**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 56609

**Manuscript Type:** MINIREVIEWS

# **COVID-19 pandemic: Its impact on liver disease and liver transplantation**

Sahin TT *et al.*SARS-Cov-2 *vs* immunocompromised liver transplant patients

Tevfik Tolga Sahin, Sami Akbulut, Sezai Yilmaz

**Tevfik Tolga Sahin, Sami Akbulut, Sezai Yilmaz,** Deaprtment of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya 244280, Turkey

**Author contributions**: Akbulut S and Sahin TT conceived the project and designed research; all authors wrote the manuscript and reviewed final version.

**Corresponding author: Sami Akbulut, MD, Associate Professor,** Deaprtment of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Elazig Yolu 10. Km, Malatya 44280, Turkey. akbulutsami@gmail.com

**Received:** May 7, 2020

**Revised:** May 23, 2020

**Accepted:** June 9, 2020

**Published online:** June 14, 2020

# **Abstract**

Severe pulmonary disease caused by the novel **coronavirus [severe acute respiratory syndrome coronavirus 2 (**SARS-CoV-2)], has devastated many countries around the world. It has overwhelmed the medical system. The priorities of many institutions have changed to manage **critically** ill corona virus infectious disease-2019 (COVID-19) patients, which affected the working style of many departments. Hepatologists and transplant surgeons **look after** a very sensitive patient group. Patients with liver disease need special attention and continuous follow-up. Similarly, transplant candidates also need special care. Healthcare professionals in the field of hepatology face the overwhelming task of taking care of COVID-19 patients with hepatic complications, liver disease or transplant patients who are SARS-CoV-2 positive, and the patients on routine surveillance who do not have COVID-19. This review will evaluate COVID-19 from the perspective of its effect on the liver and its possible effects on patients with liver disease. Furthermore, the level of care for liver transplant recipients during the pandemic will be discussed.

**Key words:** SARS-Cov-2; COVID-19; Acute liver injury; Chronic liver disease; Liver transplantation; Risk factors

Sahin TT, Akbulut S, Yilmaz S. COVID-19 pandemic: Its impact on liver disease and liver transplantation. *World J Gastroenterol* 2020; 26(22): 2987-2999

URL: https://www.wjgnet.com/1007-9327/full/v26/i22/2987.htm

# DOI: https://dx.doi.org/10.3748/wjg.v26.i22.2987

**Core tip**: Data regarding **the effect of** the **severe acute respiratory syndrome coronavirus 2 (**SARS-CoV-2) infection on liver transplant (LT) recipients are very limited. We have performed 35 living donor liver transplantations since the first corona virus infectious disease-2019 (COVID-19) case was observed in Turkey. We routinely test living liver donors and recipients for SARS-CoV-2 with nasopharyngeal swabs before the liver transplantation procedure. Furthermore, we repeated this test before discharging the patients. We have not found any SARS-CoV-2-positive LT recipients or donors, nor have we found any patients with COVID-19-like pneumonia. We have limited the number of patients going to **the outpatient clinic**, and only performed LT when it was urgently needed. We took the necessary precautions to protect the healthcare personnel by limiting the duration of work and providing protective equipment to all, including inpatients.

**INTRODUCTION**

A new strain of c**oronavirus** that caused severe respiratory disease in infected individuals was initially identified in China’s Wuhan City in December 2019[1]. The International Committee on Taxonomy of Viruses named the new virus: Severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2), which was responsible for the corona virus infectious disease-2019 (COVID-19)[2]. It soon spread to almost every country around in the world, and **the** World Health **Organization** declared that COVID-19 was a Public Health Emergency of International Concern on January 30, 2020. To date, there are 5061476 confirmed cases and 311475 deaths globally[1]. In Turkey, the first case was declared on March 11, 2020, and as this review article was written, there are 154500 confirmed cases and 4276 deaths due to COVID-19 (total test: 1767495)[3].

Themortality rate of the disease is thought to be 2%-5% in **the general** population. However, patients who were older, or had underlying diseases, such as hypertension, diabetes, and chronic obstructive pulmonary disease, are considered high-risk with a mortality rate of > 50%[4]. To date, there is no definitive treatment for COVID-19. However, agents such as remdesivir are effective in decreasing the duration to recovery and the incidence of the respiratory disease and seems promising[5]. Although respiratory symptoms dominate the clinical picture in COVID-19, it is unclear whether the virus causes infections in multiple organs. The present study aimed to evaluate the pathophysiology of COVID-19 and to analyze the implications of this disease for medical centers that facilitate and manage liver transplantation and acute and chronic liver disease.

## **PATHOGENESIS OF SARS-COV-2 INFECTION**

SARS-CoV-2 is a new virus belonging to the beta coronavirus genus[6], and is a positive-strand RNA virus that has a glycolipid envelope[7]. The virus recognizes the **angiotensin-converting** enzyme 2 (ACE-2) receptor to infect host cells[8]. This section will attempt to delineate the viral entry and replication process. ACE-2 is present in cardiomyocytes and most endothelial cells except for those lining the liver sinusoids, lungs, bile ducts, intestines, and kidneys[9]. Through the infection of these tissues, the virus can be isolated from blood, feces, urine**,** and secretions of the upper and lower respiratory. In other **words**, although the main route of entry into the body is through inhalation of respiratory microparticles**, the oral-fecal** route cannot be dismissed because viral RNA has been found in fecal samples[10].

The spike protein (S protein) is a ligand on the **SARS-CoV-2** surface that binds to ACE-2. Potential targets for this protein include ACE-2 and C-type lectin (L-SIGN or CD209L)[11]. After attaching to the cell membrane, the virus is internalized when the viral envelope fuses with the host membrane[12]. The viral genome enters the cytoplasm and is translated to form new virions. There are two open reading frames (ORFs) in the viral genome (ORF1 and ORF2)[13]. Translation of ORF1 yields structural and nonstructural proteins, which facilitates **viral** genome replication[14,15].

Once the structural proteins are formed, massive copies of **the viral** genome are synthesized. The structural proteins are incorporated into the membrane of the endoplasmic reticulum (ER) and Golgi complex[14]. Once the viral genome is replicated, it interacts with and becomes attached to the structural proteins and this complex enters the lumen of the ER-Golgi intermediary compartment (ERGIC) to form a nucleocapsid[16]. Once this process is completed, mature virions are transported to the cell membrane inside ERGIC vesicles and released into the extracellular space upon vesicles-membrane fusion[16].

## **THE INTERACTION OF SARS-COV-2 AND THE IMMUNE SYSTEM**

### ***The role of the major histocompatibility antigens***

The viral nucleocapsid proteins remain on the surface of the cell membrane after the virus has entered the cell *via* fusion with the host membrane; these are recognized by **antigen-presenting** cells, which initiate an antiviral immune response[7]. The common antigen presenting cells in humans are dendritic cells, monocytes, plasma cells, *etc*. Viral antigens are presented to cytotoxic (CD8+) and regulatory (CD4+) T lymphocytes by the major histocompatibility complexes, which are also called human leukocyte antigens (HLAs). In particular, HLA class I antigens play an important role during this process[17].

We know very **little** about SARS-CoV-2 and the antigens involved in the immune response to this virus. However, our experience with the 2003 SARS pandemic has provided important information regarding the role of HLA class I and II antigens. From the SARS pandemic, we know that certain HLA class I and II alleles, such as HLA IB4601, IB07033, and IIDRB1-1202[18,19], increase an individual’s susceptibility to coronavirus. In contrast, the HLA II DR0301, Cw1502, and IA 0201 alleles confer resistance to SARS and Middle-East respiratory syndrome (MERS) infections[20].

### ***Interaction of SARS-CoV-2 with components of the host immune system***

Our current SARS-CoV-2 knowledge is based on our experiences from previous pandemics (SARS and MERS). Unfortunately, the host-viral interactions for SARS-CoV-2 have not been clearly defined. However, we can follow its immunopathogenesis based on our observations of patient symptoms[21,22]. People become infected when they breathe in the respiratory secretions (droplets and microdroplets) from infected individuals come into contact with their respiratory tract. The median interval between the exposure to the development of the symptoms is 6 d (range: 2-14 d)[2,11,23]. The main features in infected patients were lymphopenia and elevated serum levels of pro-inflammatory cytokines[11,23,24]. Chronologically, these phenotypes coincide with **the appearance** of bilateral “ground glass” opacities in the lungs[21]. Lin and colleagues hypothesized that the viral cycle has three phases: (1) Viral entry and viremia; (2) pneumonia; and (3) recovery phase[21]. The first two phases occur in all patients when **SARS-CoV-2 somehow** evades the immune system. If the immune system is strong and **the virus** is cleared away, the patient recovers. However, if the immune system is dysfunctional, such as in individuals with hypertension, cardiovascular disease, or diabetes, there will be a late inflammatory response that results in **a cytokine** storm. In this scenario, **the patient’s** condition deteriorates to a critical level[21,25]. In the present section, we summarize the interactions between the virus **and the components** of **the innate** and adaptive immune system.

The main mechanism for viral immune evasion begins at the innate immune response level. Viral defense against the host immune system involves: (1) infection of **a limited** number of cells over a large surface area; and (2) blockage of the main host immune defense, such as the interferon (IFN) type I response and its **downstream** pathways[25]. As we have stated earlier, **the main** receptor for SARS-CoV-2 cellular entry is **ACE-**2, and **the main** entry route to the body is *via* inhalation of microdroplets into the lower respiratory tract. The ACE-2-positive alveolar cells comprise only a fraction of the cells of the respiratory tract[9,26]. Therefore, only a limited number of cells across a large surface area are initially infected, which may “dilute” the initial viral load. As a result, density of infected cells are initially low and virus replicating and disseminating without evoking a major response in the host immune system. The IFN type I pathway plays a key role in the initial defense against viral infection. **Pathogen-associated** molecular patterns, which constitute the viral RNA and the intermediate **double-stranded** RNAs that are formed during viral replication, are recognized by certain receptors on the ER, which initiates an internal signal for the IFN type I response. Downstream of this pathway, the Janus kinases and signal transducer and activator of transcription proteins are phosphorylated and activated, and the **IFN-stimulated** genes are transcribed. The IFN related genes are comprised of vast number of chemokines and cytokines that stimulate both then innate and the adoptive immune system. All these result in apoptosis of the infected cells and immune cell recruitment[16]. Both SARS and MERS **coronaviruses** block the IFN type I response by either dephosphorylating or ubiquitinating the intracellular receptors and effectors in this pathway[27]. SARS-CoV-2 could also inhibit this pathway *via* the same mechanism because it is genomically similar to the SARS (80%) and MERS (nearly 50%) viruses[28]. Furthermore, our experiences with SARS and MERS showed us that **coronaviruses** could infect local macrophages and T cells[29]. The innate immune system plays an important role in the clearance of the virus. If the innate immune system is successful in clearance of the virus in the early stages then the infection resolves without any problem. However, if the viral clearance is unsuccessful, the late IFN type I response results in the release of a variety of proinflammatory cytokines are synthesized and released which results in a hyperinflammatory state which is called the cytokine storm. Therefore, the efficiency of the function of the innate immune system determines the prognosis of the[7,25]. In individuals with **an intact** innate immune system, the virus is cleared during the initial phase, and this is the reason why children and healthy young adults who contract the disease have mild symptoms. However, **the elderly** and individuals with underlying chronic diseases have an altered innate immune response and the viral clearance is not sufficient leading to cytokine storm and which has devastating effects[24].

In certain patient groups with poorer prognostic outcomes, **the** discharge of cascade of pro-inflammatory cytokines (cytokine storm syndrome) results in a hyper-inflammatory state, which exacerbates **pulmonary** dysfunction and may lead to multi-organ failure[29]. Cardinal feature of the cytokine storm syndrome resemble hemophagocytic lymphocytosis. Both entities manifest as persistent fever, cytopenia, and hyperferritinemia. Pulmonary dysfunction is also a prominent feature of this disease, affecting more than 50% of patients[30]. Huang and colleagues[24] showed that the levels of pro-inflammatory cytokines, such as interleukin (IL)-2, IL-7, granulocyte **colony-stimulating** factor (GM-CSF), IFN-ɣ inducible protein (IP)-1, monocyte chemoattractant protein (MCP), macrophage inflammatory protein (MIP)-1α, and tumor necrosis factor (TNF)-α are increased in COVID-19 patients. Yang *et al*[31] analyzed 53 COVID-19 cases (34 severe versus 19 moderate). They showed that patients with moderate disease were generally younger (63.2% were between 16-59 years of age in moderate cases; 73.5% of severe cases were over 60 years old). Both pro- and anti-inflammatory cytokines were elevated in the COVID-19 cases. In particular, IP-10, MCP-3, and IL-1ra levels predicted the disease severity and mortality of patients because these cytokines were persistently elevated in a majority of severe cases (for up to 15 d from admission) and 14 fatal cases[31]. Therefore, **cytokine** storm syndrome is a potential target for developing new therapeutic modalities to treat critical cases and to reduce mortality. Monteleone *et al*[32] published **an editorial** proposing that patients should be treated with anti-IL-6 therapy, normally used to treat hyperactive immune diseases, such as rheumatoid arthritis, as it may protect patients from the pulmonary complications observed in COVID-19 patients. This may be due to the fact that IL-6 lies at the center of the cytokine cascade involved in **cytokine** storm syndrome.

The type 1 T helper response to viral infections is extremely importantbecause it provides **a memory** response against the virus. It is important to orchestrate humoral and **cytotoxic** T cell responses during viral infections[25,33]. This adaptive immune response targets certain viral antigens, such as the S, N, M, and E proteins. While there are insufficient data on the adaptive immune response to SARS-CoV-2; our experience from SARS patients tells us that the immunoglobulin (Ig)M response begins 9 d post-infection, and continues for 12 wk[25,34]. **In** the second week following viral entry, IgG response kicks in. The IgG response can be observed for up to two years after the initial viral infection[34]. The number of peripheral blood CD4+ and CD8+ lymphocytes is reduced in COVID-19 patients and we do nor know the implications of this observation[7,35]. However, during the SARS pandemic, the CD4+ T cell activity is overwhelmed by the CD8+ T cell response. Furthermore, a type 2 T helper response was observed in patients with severe disease, and elevation of IL-4, IL-5, and IL-10 cytokines was the dominant immune response in critically ill patients[36]. **In** addition, early cytotoxic T cell responses predicted disease severity and mortality in patients[37]. Cumulatively, these results suggest that we should focus on promoting the type 1 T helper responses and preventing excessive cytotoxic T cell responses in patients when developing treatment and vaccination for COVID-19.

## **ACUTE LIVER INJURY IN PATIENTS WITH COVID-19**

The SARS-CoV-2 S protein is expressed in tissues during the viral replication cycle and causes inflammation in most tissues, including the liver. This inflammatory response **facilitates viral** clearance from the tissues and promotes an adaptive immune response to viral infection[38]. CD4+ lymphocytes promote the transformation of B cells into plasma cells and enhance antibody production. Cytotoxic T lymphocytes are active in most tissues, which reflects an effective antiviral response, but may also cause extensive tissue injury. Therefore, as previously mentioned, events that lead to a **hyper-inflammatory** state cause tissue immunopathogenesis, which may result in tissue injury **during COVID-19**[39]. However, the exact mechanisms by which an extrapulmonary organ, such as the liver, is affected by SARS-CoV-2 infection is **not known**. In this section, we will summarize the current cases and outline the liver-related pathologies in these patients.

One of the points of discussion for this subject is whether viral liver injury occurred as a direct or indirect consequence of COVID-19[38]. ACE-2 is expressed by cholangiocytes but not by Kupffer cells, hepatocytes, or sinusoidal endothelial cells[9,40]. In animal models, ACE-2 expression was elevated after partial hepatectomy, which was maintained until the end of the regenerative process[41]. This elevated expression was attributed to an increase in cholangiocyte activity, including its own proliferation and differentiation to hepatocyte differentiation[38,42]. Therefore, ACE-2 is a surrogate marker for hepatic regeneration. We hypothesized that in living donor liver transplantation (LDLT), the ACE-2 protein is also upregulated in the tissue and serum. Therefore, during the early postoperative phase, both the liver transplant (LT) recipients and donor tissues are more susceptible to SARS-CoV-2 infection because they have an elevated ACE-2 protein expression as a consequence of hepatic regeneration.

Gamma-glutamyltransferase and alkaline phosphatase are known surrogate markers of cholangiocyte and bile duct damage[38]. Patient data accumulated since the beginning of the pandemic in Wuhan, China, have shown that the level of aminotransferase had increased, whereas, that of cholestatic enzymes had not (Table 1)[4,24,42-50]. Approximately 20% of cases in descriptive and phase IV clinical trials of new therapeutic approaches had elevated aminotransferase[48]. Furthermore, the duration and severity of this disease affected **aminotransferases levels**, which peaked at around the second and third week following the onset of symptoms[44,49]. This observation suggests that the mechanistic basis of tissue injury may not be directly related **to the** viral infection.

**The liver** is a highly intricate filtration machine that detoxifies portal blood of the xenobiotics that originate from the intestines. This liver function can be disrupted by extreme physiological stress. Cytokine storm is one of the most potent physiological stresses that **result** in a hyper-inflammatory condition and leads to **organ** damage[51,52]. High levels of IL-2, IL-6, IL-7, IL-10, TNF-α, GM-CSF, IP-10, MCP-1, and MIP-1α were observed in patients with severe COVID-19[51,52]. Furthermore, acute liver injury was more prominent in these patients[47]. For this reason, there must be a correlation between acute liver injury and cytokine storm, both of which were observed in **the severe** form of COVID-19.

Sepsis is a common clinical condition in COVID-19 patients and **is also a major** physiological stress[38,53]. Many mechanisms can cause end-organ damage during sepsis. Reactive oxygen species, ischemia-reperfusion injury, **sepsis-induced** cholestasis, and drug toxicity injury are some of the mechanisms that could cause **sepsis-induced** liver injury. Furthermore, hypo-perfusion and a hyper-inflammatory state result in an unfavorable microenvironment that leads to liver injury[54,55]. The main COVID-19 liver damages are moderate microvesicular steatosis and mild inflammation at the lobules and portal region, which reflects drug toxicity[35,56]. COVID-19 patients consume certain drugs, such as paracetamol, oseltamivir, abidol, and lopinavir/ritonavir, which are known to be hepatotoxic[57,58]. Therefore, a combination of **virus-mediated hyper-inflammatory** state and drug hepatotoxic result in the acute liver injury observed in COVID-19 patients. However, the effects of SARS-CoV-2 infection on patients with underlying liver diseases, such as hepatitis B virus (HBV) and hepatitis C virus infections, non-alcoholic steatohepatitis, and ethanol toxicity, are **not known**. The following sections will evaluate the effect of SARS-CoV-2 in patients with chronic liver disease and those who have undergone liver transplantation.

# **COVID-19 IN PATIENTS WITH UNDERLYING LIVER DISEASE**

Although evidence is lacking, patients with chronic liver diseases may be more susceptible to SARS-CoV-2 infection. Biologic drugs used to treat COVID-19, such as tocilizumab and baricitinib, can result in the reactivation of diseases, such as HBV infections[56]. There are two points to be considered. The first is **SARS-CoV-2’s effect** on patients with underlying liver disease, and the second is how this virus changes the standard of care for patients with liver disease.

While we do not have enough clinical evidence to properly dissect the first point, an early postmortem study has shown that the virus was found in **the liver** tissue of a patient who had died from COVID-19[59]. In the same study, one patient had cirrhosis, but the liver **histopathologic** examination result was inconclusive. However, three other patients who did not have a history of liver disease exhibited signs of hepatic damage, such as nuclear glycogen deposition, microvesicular steatosis, zone 3 sinusoidal dilatation, patchy hepatic necrosis, and minimal lymphocytic infiltration[59]. Therefore, in terms of its role in the liver, COVID-19 may worsen liver disease by attacking the remaining parenchyma. Our hypothesis is supported by several Chinese clinical studies that showed that 2% of patients with severe COVID-19 also had HBV infection, in comparison to 0.6% with non-severe SARS-CoV-2 pneumonia[42,60]. This suggests that patients infected by HBV tend to have a more severe form of SARS-CoV-2. Furthermore, the drugs used to treat COVID-19 **are** hepatotoxic, which complicates the clinical situation of liver disease **patients**[60]. A literature search has not identified any association between fulminant hepatic failure and COVID-19 or that this virus could synergize with factors, such as drugs and viral agents that induce acute liver failure. However, this is due to **a paucity** of data rather than the effect of the virus. Table 2 summarizes the clinical data of patients with chronic liver disease that were infected by SARS-CoV-2[24,42,43,47,48,61,62]. In brief, 2543 COVID-19 patients with a complete medical history (including the severity of disease and outcome) were reported in the literature. Among these patients, 103 had either cirrhosis or HBV-related diseases (4%). Among the patients with cirrhosis, the incidence of severe disease varied between 4.3% to 71.4% in various studies[24,42,43,47,49,61,62]. Luo and colleagues reported thatthe mortality rate for COVID-19 patients with pre-existing liver disease was **approximately** 30%-36%[61,62]. Therefore, although the incidence of patients with both pre-existing liver disease and COVID-19 is low, their mortality rate is high (close to 40%), which necessitates taking extra precautions for this patient group.

Various societies have recommended that patients with **pre-existing** liver disease should be managed as follows during the pandemic to reduce the health risks: (1) postpone outpatient visits for chronic liver diseases that were not hepatocellular carcinoma (HCC) and promote online consultation for these patients; (2) non-urgent procedures, including elective endoscopy and biopsies, should be postponed; (3) caring for decompensated cirrhosis, HCC, or transplant patients should continue with the same standards; (4) always provide protective equipment to protect patients and healthcare workers; and (5) screen for SARS-CoV-2 when necessary[63-69]. Special care should be taken when treating SARS-CoV-2 positive patients because the antivirals used to treat COVID-19 are hepatotoxic and interfere with molecules important for liver functions (*e.g*., cytochrome P450, family 3, subfamily A, CYP A3). Therefore, treatment doses should be reduced for patients with liver disease[69].

# **THE IMPORTANCE OF COVID-19 TO LIVER TRANSPLANTATION CENTERS**

In this section, we summarize the studies on COVID-19 infection in LT recipients and a living liver donor (LLD)-to-recipient transmission of this virus. D’Antiga[70] (Bergamo, Italy), who is from one of the biggest pediatric LT facilities in Europe, commented that, based on his experience with SARS and MERS, LT recipients were not specifically at increased risk from COVID-19. In our opinion, this is a very unfortunate statement based on very premature data. Interestingly, they also showed that of the 700 children treated for various liver diseases, 200 were LT recipients, 3 of these were infected with SARS-CoV-2, and none of them had pneumonia-related symptoms. However, we do not know what happened to these three LT recipients[70]. We are very interested in their current situation **because** Italy is now the country with the **most COVID-19-related** deaths in Europe.

Bhoori *et al*[71] followed 151 patients who had received LT (111 long-term and 40 short-term LT recipients). In their study, three long-term LT recipients (2.7%) had died from severe COVID-19, and three short-term LT recipients (7.5%) were SARS-CoV-2 positive but had survived the disease. The long-term LT recipients were significantly older (50% of long-term LT recipients and 30% of short-term LT recipients were ≥ 65 years), and were more likely to be obese (80% long-term and 60% short-term), diabetic (60% long-term and 23% short-term), and hypertensive (100% long-term and 68% short-term)[71]. These pathologies can be attributed to the long-term use of **immunosuppressant** medications. In a report by Huang *et al*[72], a 59 years old male patient, who had LT in 2017 to treat HBV-related HCC, was transmitted SARS-CoV-2 by his wife. The clinical picture was complicated by chronic graft rejection, and the patient passed away **26 d** later from polymicrobial sepsis. The patient initially developed severe pneumonia, empyema, and pneumothorax, which rapidly progressed to multi-organ failure[72]. Liu *et al*[73] reported on a 50 years old male patient who had received a deceased donor LT in 2017 for HBV-related liver failure. The patient developed severe COVID-19 pneumonia 6 **d** after the onset of symptoms and fully recovered after 2-mo of treatment[73]. Qin *et al*[74] reported on a 37 years old male patient who had LT for HBV-related HCC and had traveled to an endemic area and contracted severe COVID-19 during the perioperative period. Fortunately, the patient recovered; however, **he was** found to be shedding the virus 53 d post-“recovery”[74]. We believe that LT patients are **specifically** at **risk from** COVID-19 and may also be a public health burden because the virus clears at a slower rate from these patients, potentially due to the chronic use of immunosuppressants and therefore these patients may become long-term carriers.

Contrary to D’Antiga[70]’s report, Lagana *et al*[75] reported that a 6-mo old infant with biliary atresia, who had received LDLT from her COVID-19-positive mother, was infected *via* this transplant and developed severe pneumonia and hepatitis. A core biopsy obtained on the postoperative seventh day showed infiltration of the portal tracts inflammatory and plasma cells and mild interlobular cholangitis and portal perivenulitis. She was initially treated for T-cell-mediated rejection; however, **her** illness was aggravated upon increase use of immunosuppressant and subsided once immunosuppression was tapered off. Fortunately, the patient fully recovered[75], and she did not need intubation.

According to the current literature, a total of 13 COVID-19 patients had undergone LT (assuming that the patients reported by D’Antiga[70] were post-transplant when they had contracted COVID-19), 7 developed severe pneumonia (53.8%), and 4 died (30.7%) from severe pulmonary infection leading to multi-organ failure[70-75]. In adults, four out of nine patients with SARS-CoV-2 developed severe pneumonia and had died. A further three patients were asymptomatic carriers who did not develop symptoms. Four adult LT recipients were short-term liver recipients, and **the** remaining five were long-term recipients, of which four had died from severe pneumonia and sepsis[70-75]. There were four pediatric patients, and only one of these had developed severe pneumonia and hepatitis[70-75]. The published cases are summarized in Tables 3 and 4. In our opinion, these results are alarming, and these patients should have been classified as an at-risk group and should have received regular surveillance for COVID-19 throughout the pandemic. Therefore, **the** recommendations of certain societies are important when establishing precautionary measures **to take in LT** centers. In the later part of this section, we will summarize the recommendations from highly respected international and Turkish societies.

Liu *et al*[69] (Beijing working party for liver transplantation) stated that the LT patients who are permanently on immunosuppressants could be particularly susceptible to SARS-CoV-2, and their prognosis could be worse in comparison to **the** normal population. This group recommended that both the LLDs and LT recipients should be closely monitored for SARS-CoV-2, including keeping a detailed history of contacts with high-risk individuals. Furthermore, they suggested that all the health personnel and patients should wear protective equipment until the patient is cleared of SARS-CoV-2 risk[69].

A **position paper written jointly by the** European Association of the Study of the Liver (EASL) and the European Society of **Clinical Microbiology and Infectious Disease (****ESCMID) recommended that all patients scheduled for LT should be tested for SARS-CoV-2 and** informed of the nosocomial COVID-19 risk[63]. Furthermore, LDLT should be restricted, and each center should evaluate any operations on a case by case bases. LTs should be restricted to patients with acute or acute chronic liver failure with high model for **end-stage** liver disease (MELD) scores and HCC patients at the upper limits of the Milan criteria[63]. The Turkish Association for the Study of the Liver recommended that all elective **procedures** be postponed, and only emergency operations should be performed provided that the required facilities are available (*e.g*.,a suitable inpatient ward)[65]. The American **Association** for Study on Liver Diseases provided similar recommendations: that LT should be limited to **emergency cases** (*e.g*., patients with high MELD scores) or HCC patients who are at risk of disease progression and removal from the waiting list[64]. The Turkish Surgical Society recommended that all elective and laparoscopic procedures be **canceled**[76]. Urgent procedures should be performed under strict isolation conditions for the staff in a well-ventilated laminar flow-equipped operating room and only minimal number of personnel and equipment allowed[76]. The LT society of India (LTSI) highlighted the potential of LT recipients as asymptomatic carriers and **source** of viral spread[77], and that SARS-CoV-2 can be transmitted from LLDs to LT recipients. **In addition**, they stated that a longer hospitalization period for these patients increases **the risk** of nosocomial viral spread since the hospitals have many COVID-19 patients. The LTSI recommended that elective procedures be postponed, and both deceased donors and LLDs be tested for SARS-CoV-2. Only emergency procedures for acute and acute-on-chronic liver failure should be performed, and general hospital visits for patients on surveillance should be limited[77]. The British **Association** for the Study of the **Liver** and British Liver Transplant Group sent out a joint statement recommending that all LT recipients should take the necessary precautions to reduce the spread of SARS-CoV-2, which includes using protective equipment and frequent **handwashing**[78]. Furthermore, they suggested l**imiting hospital** visits, unless in the event of a medical emergency[78].

There are insufficient data on the relationship between immunosuppressive therapy and COVID-19 in LT recipients during this pandemic. However, the Beijing working party for liver transplantation suggested that LT recipients who were infected with SARS-CoV-2 should be treated with steroids for a short period to reduce the severity of pneumonia[69]. They also suggested that immunosuppressive therapies should be continued for both patients with mild COVID-19 and those who were not infected by the virus, and calcineurin inhibitor treatment dosage should be reduced in moderate to severe cases[69]. In contrast, the EASL-ESCMID position statement suggested that the immunosuppressive medication dosage could be adjusted according to the antiviral treatment protocols because there is a high chance that the drugs from both treatment protocols could interact[63].

There is very limited data for LT recipients, and the effectiveness of the above societies’ recommendations is unknown. Our LT institute is classified as a center of excellence for LDLT, and we perform 250 to 300 LT annually. We have performed 35 LDLT (34 semi-urgent and 1 emergency) procedures since the first Turkish COVID-19 case **o**n March **11**, 2020, of which 4 were pediatric patients and 31 were adult recipients. We routinely test LLD candidates and their LT recipients for SARS-CoV-2 by nasopharyngeal swabs before LT surgery. Furthermore, we repeat the same test before discharging the patients. We have not encountered a SARS-CoV-2-positive LT recipient or donor, and none of our patients exhibited severe COVID-19 pneumonia. We have limited the number **of** patients in **our outpatient** clinic and only performed LT for cases that were of urgent need. We took the necessary precautions for our healthcare personnel by limiting the duration of patient interaction and providing protective equipment to everyone, including the inpatients. These precautions appear to be useful in reducing the number of cases. However, we should approach with caution when we make such a statement because that there is **still** a long time **ahead** of us and the disease is still spreading in Turkey.

**CONCLUSION**

COVID-19 is the cause of a **worldwide** tragedy. These are unprecedented times that a healthcare provider hopes that he or she will never **encounter throughout** their career. It has limited our social life, dictated the way we work, and has resulted in a very isolated and limited **lifestyle**. Unfortunately, as healthcare providers, we have to take care of patients with COVID-19 and also continue our professional and social activities. We belonged to a sub-specialty **that deals** with a terminally ill patient group. The data **suggest** that patients with liver disease and transplant candidates are particularly **at** risk from COVID-19. We are still a long way from having a definitive treatment or vaccine. We are faced with treating a deadly infection in a very susceptible group; therefore, we, the healthcare providers, should have an understanding of the disease, should be able to take the necessary precautions to ensure the safety of both our patients and ourselves. Furthermore, we should be ready for the worst and prepare our institution accordingly. Prevention is the best treatment; therefore, we should try to protect our patients from being infected by postponing non-priority procedures or visits to the hospital. Telemedicine could be used to monitor patients, and online platforms could be set up for patients to discuss their health status with physicians. If prevention is impossible, isolation techniques should be employed by both staff and patients, routine SARS-CoV-2 surveillance should be performed, and the facility should be arranged to manage these patients accordingly.

**REFERENCES**

1 **WHO**. World Health Organization Coronavirus disease (COVID-19) situation Dashboard. 2020 [cited 23 May 2020]. Available from: <https://covid19.who.int>

2 **Zhou P**, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; **579**: 270-273 [PMID: 32015507 DOI: 10.1038/s41586-020-2012-7]

3 COVID-19 Yeni Koronavirüs Hastalığı. 2020 [cited 22 May 2020]. Available from: <https://covid19.saglik.gov.tr>

4 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

5 **Beigel JH**, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med* 2020 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]

6 **Lu R**, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; **395**: 565-574 [PMID: 32007145 DOI: 10.1016/S0140-6736(20)30251-8]

7 **Li X**, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal* 2020; **10**: 102-108 [PMID: 32282863 DOI: 10.1016/j.jpha.2020.03.001]

8 **Li W**, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003; **426**: 450-454 [PMID: 14647384 DOI: 10.1038/nature02145]

9 **Hamming I**, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004; **203**: 631-637 [PMID: 15141377 DOI: 10.1002/path.1570]

10 **Gu J**, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. *Gastroenterology* 2020; **158**: 1518-1519 [PMID: 32142785 DOI: 10.1053/j.gastro.2020.02.054]

11 **Wu F**, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. *Nature* 2020; **579**: 265-269 [PMID: 32015508 DOI: 10.1038/s41586-020-2008-3]

12 **Simmons G**, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc Natl Acad Sci U S A* 2004; **101**: 4240-4245 [PMID: 15010527 DOI: 10.1073/pnas.0306446101]

13 **Fehr AR**, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol* 2015; **1282**: 1-23 [PMID: 25720466 DOI: 10.1007/978-1-4939-2438-7\_1]

14 **Wang H**, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res* 2008; **18**: 290-301 [PMID: 18227861 DOI: 10.1038/cr.2008.15]

15 **Kuba K**, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. *Pharmacol Ther* 2010; **128**: 119-128 [PMID: 20599443 DOI: 10.1016/j.pharmthera.2010.06.003]

16 **de Wit E**, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol* 2016; **14**: 523-534 [PMID: 27344959 DOI: 10.1038/nrmicro.2016.81]

17 **Liu J**, Wu P, Gao F, Qi J, Kawana-Tachikawa A, Xie J, Vavricka CJ, Iwamoto A, Li T, Gao GF. Novel immunodominant peptide presentation strategy: a featured HLA-A\*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. *J Virol* 2010; **84**: 11849-11857 [PMID: 20844028 DOI: 10.1128/JVI.01464-10]

18 **Keicho N**, Itoyama S, Kashiwase K, Phi NC, Long HT, Ha LD, Ban VV, Hoa BK, Hang NT, Hijikata M, Sakurada S, Satake M, Tokunaga K, Sasazuki T, Quy T. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. *Hum Immunol* 2009; **70**: 527-531 [PMID: 19445991 DOI: 10.1016/j.humimm.2009.05.006]

19 **Chen YM**, Liang SY, Shih YP, Chen CY, Lee YM, Chang L, Jung SY, Ho MS, Liang KY, Chen HY, Chan YJ, Chu DC. Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. *J Clin Microbiol* 2006; **44**: 359-365 [PMID: 16455884 DOI: 10.1128/JCM.44.2.359-365.2006]

20 **Wang SF**, Chen KH, Chen M, Li WY, Chen YJ, Tsao CH, Yen MY, Huang JC, Chen YM. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. *Viral Immunol* 2011; **24**: 421-426 [PMID: 21958371 DOI: 10.1089/vim.2011.0024]

21 **Lin L**, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. *Emerg Microbes Infect* 2020; **9**: 727-732 [PMID: 32196410 DOI: 10.1080/22221751.2020.1746199]

22 **Lauer SA**, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020; **172**: 577-582 [PMID: 32150748 DOI: 10.7326/M20-0504]

23 **Wong CK**, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol* 2004; **136**: 95-103 [PMID: 15030519 DOI: 10.1111/j.1365-2249.2004.02415.x]

24 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

25 **Prompetchara E**, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pac J Allergy Immunol* 2020; **38**: 1-9 [PMID: 32105090 DOI: 10.12932/AP-200220-0772]

26 **Zhu N**, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727-733 [PMID: 31978945 DOI: 10.1056/NEJMoa2001017]

27 **Channappanavar R**, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 2017; **39**: 529-539 [PMID: 28466096 DOI: 10.1007/s00281-017-0629-x]

28 **Perlman S**, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. *Nat Rev Immunol* 2005; **5**: 917-927 [PMID: 16322745 DOI: 10.1038/nri1732]

29 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: 32192578 DOI: 10.1016/S0140-6736(20)30628-0]

30 **Seguin A**, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. *Chest* 2016; **149**: 1294-1301 [PMID: 26836913 DOI: 10.1016/j.chest.2015.11.004]

31 **Yang Y**, Shen C, Li J, Yuan J, Yang M, Wang F, Li G, Li Y, Xing L, Peng L, Wei J, Cao M, Zheng H, Wu W, Zou R, Li D, Xu Z, Wang H, Zhang M, Zhang Z, Liu L, Liu Y. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. 2020 Preprint. Available from: MedRxiv [DOI: 10.1101/2020.03.02.20029975]

32 **Monteleone G**, Sarzi-Puttini PC, Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. *Lancet Rheumatol* 2020; **2**: e255-e256 [PMID: 32368737 DOI: 10.1016/S2665-9913(20)30092-8]

33 **Liu WJ**, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. *Antiviral Res* 2017; **137**: 82-92 [PMID: 27840203 DOI: 10.1016/j.antiviral.2016.11.006]

34 **Liu W**, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, Tang F, Lv H, Cao WC. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. *J Infect Dis* 2006; **193**: 792-795 [PMID: 16479513 DOI: 10.1086/500469]

35 **Xu Z**, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420-422 [PMID: 32085846 DOI: 10.1016/S2213-2600(20)30076-X]

36 **Li CK**, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin CL, Screaton GR, Hou JL, McMichael AJ, Xu XN. T cell responses to whole SARS coronavirus in humans. *J Immunol* 2008; **181**: 5490-5500 [PMID: 18832706 DOI: 10.4049/jimmunol.181.8.5490]

37 **Shin HS**, Kim Y, Kim G, Lee JY, Jeong I, Joh JS, Kim H, Chang E, Sim SY, Park JS, Lim DG. Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection. *Clin Infect Dis* 2019; **68**: 984-992 [PMID: 30060038 DOI: 10.1093/cid/ciy595]

38 **Li J**, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. *J Clin Transl Hepatol* 2020; **8**: 13-17 [PMID: 32274341 DOI: 10.14218/JCTH.2020.00019]

39 **Li G**, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J. Coronavirus infections and immune responses. *J Med Virol* 2020; **92**: 424-432 [PMID: 31981224 DOI: 10.1002/jmv.25685]

40 **Uhlén M**, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human proteome. *Science* 2015; **347**: 1260419 [PMID: 25613900 DOI: 10.1126/science.1260419]

41 **Guan GW**, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, Zhang T, Chen XM, Lu FM. [Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia]. *Zhonghua Gan Zang Bing Za Zhi* 2020; **28**: 100-106 [PMID: 32077659 DOI: 10.3760/cma.j.issn.1007-3418.2020.02.002]

42 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

43 **Hu L**, Chen S, Fu Y, Gao Z, Long H, Wang JM, Ren HW, Zuo Y, Li H, Wang J, Xu QB, Yu WX, Liu J, Shao C, Hao JJ, Wang CZ, Ma Y, Wang Z, Yanagihara R, Deng Y. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. *Clin Infect Dis* 2020 [PMID: 32361738 DOI: 10.1093/cid/ciaa539]

44 **Zhang Y**, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. *Liver Int* 2020 [PMID: 32239796 DOI: 10.1111/liv.14455]

45 **Yang W**, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. *J Infect* 2020; **80**: 388-393 [PMID: 32112884 DOI: 10.1016/j.jinf.2020.02.016]

46 **Fu L**, Fei J, Xu S, Xiang HX, Xiang Y, Tan ZX, Li MD, Liu FF, Li Y, Han MF, Li XY, Zhao H, Xu DX. Acute liver injury and its association with death risk of patients with COVID-19: a hospital-based prospective case-cohort study. 2020 Preprint. Available from: MedRxiv [DOI: 10.1101/2020.04.02.20050997]

47 **Cai Q**, Huang D, Ou P, Yu H, Zhu Z, Xia Z, Su Y, Ma Z, Zhang Y, Li Z, He Q, Liu L, Fu Y, Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* 2020 [PMID: 32239761 DOI: 10.1111/all.14309]

48 **Cao B**, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382**: 1787-1799 [PMID: 32187464 DOI: 10.1056/NEJMoa2001282]

49 **Shi H**, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; **20**: 425-434 [PMID: 32105637 DOI: 10.1016/S1473-3099(20)30086-4]

50 **Omrani-Nava V**, Maleki I, Ahmadi A , Moosazadeh M , Hedayatizadeh-Omran A , Roozbeh F, Nahanghi H, Alizadeh-Navaei R. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. Hepat Mon 2020; 20: e103179 [doi:10.5812/hepatmon.103179]

51 **Diao B**, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu YP, Wang G, Yuan Z, Feng Z, Wu Y, Chen Y. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *Front Immunol* 2020 [DOI: 10.3389/fimmu.2020.00827]

52 **Wan S**, Yi Q, Fan S, Lv J, Zhang X, Guo L, Lang C, Xiao Q, Xiao K, Yi Z, Qiang M, Xiang J, Zhang B, Chen Y. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020 Preprint. Available from: MedRxiv [DOI: 10.1101/2020.02.10.20021832]

53 **Joung JY**, Cho JH, Kim YH, Choi SH, Son CG. A literature review for the mechanisms of stress-induced liver injury. *Brain Behav* 2019; **9**: e01235 [PMID: 30761781 DOI: 10.1002/brb3.1235]

54 **Lelubre C**, Vincent JL. Mechanisms and treatment of organ failure in sepsis. *Nat Rev Nephrol* 2018; **14**: 417-427 [PMID: 29691495 DOI: 10.1038/s41581-018-0005-7]

55 **Strnad P**, Tacke F, Koch A, Trautwein C. Liver - guardian, modifier and target of sepsis. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 55-66 [PMID: 27924081 DOI: 10.1038/nrgastro.2016.168]

56 **Sun J**, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int* 2020; **40**: 1278-1281 [PMID: 32251539 DOI: 10.1111/liv.14470]

57 **Jiang F**, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). *J Gen Intern Med* 2020; **35**: 1545-1549 [PMID: 32133578 DOI: 10.1007/s11606-020-05762-w]

58 **Zhang C**, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; **5**: 428-430 [PMID: 32145190 DOI: 10.1016/S2468-1253(20)30057-1]

59 **Tian S**, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Mod Pathol* 2020 [PMID: 32291399 DOI: 10.1038/s41379-020-0536-x]

60 **Sarin SK**. "Fast, faster, and fastest: science on the run during COVID-19 drama"-"do not forget the liver". *Hepatol Int* 2020 [PMID: 32277386 DOI: 10.1007/s12072-020-10042-0]

61 **Luo XM**, Zhou W, Xia H, Yang W, Yan X, Wang B, Guo T, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B. Characteristics of SARS-CoV-2 Infected Patients with Clinical Outcome During Epidemic Ongoing Outbreak in Wuhan, China. *SSRN Electron J* 2020 [DOI: 10.2139/ssrn.3552812]

62 **Luo X**, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B, Yang W. Prognostic value of C-reactive protein in patients with COVID-19. *Clin Infect Dis* 2020 [PMID: 32445579 DOI: 10.1093/cid/ciaa641]

63 **Boettler T**, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Rep* 2020; **2**: 100113 [PMID: 32289115 DOI: 10.1016/j.jhepr.2020.100113]

64 **AASLD**. Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic. 2020: 1-28 [cited 23 May 2020]. Available from: <https://www.aasld.org/sites/default/files/2020-04/AASLD-COVID19-ClinicalInsights-4.07.2020-Final.pdf>

65 **TASL Position Statement**. COVID-19. 2020 [cited 23 May 2020]. Available from: http://wwwtaslorgtr/turkish assoc study liver position statment covıd-19

66 **Fix OK**, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. *Hepatology* 2020 [PMID: 32298473 DOI: 10.1002/hep.31281]

67 **Xiao Y**, Pan H, She Q, Wang F, Chen M. Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis. *Lancet Gastroenterol Hepatol* 2020; **5**: 528-529 [PMID: 32197093 DOI: 10.1016/S2468-1253(20)30080-7]

68 **Serper M**, Cubell AW, Deleener ME, Casher TK, Rosenberg DJ, Whitebloom D, Rosin RM. Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action? *Hepatology* 2020 [PMID: 32275784 DOI: 10.1002/hep.31276]

69 **Liu H**, He X, Wang Y, Zhou S, Zhang D, Zhu J, He Q, Zhu Z, Li G, Sun L, Wang J, Cheng G, Liu Z, Lau G. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. *Hepatol Int* 2020 [PMID: 32277387 DOI: 10.1007/s12072-020-10043-z]

70 **D'Antiga L**. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. *Liver Transpl* 2020; **26**: 832-834 [PMID: 32196933 DOI: 10.1002/lt.25756]

71 **Bhoori S**, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. *Lancet Gastroenterol Hepatol* 2020; **5**: 532-533 [PMID: 32278366 DOI: 10.1016/S2468-1253(20)30116-3]

72 **Huang JF**, Zheng KI, George J, Gao HN, Wei RN, Yan HD, Zheng MH. Fatal outcome in a liver transplant recipient with COVID-19. *Am J Transplant* 2020 [PMID: 32277591 DOI: 10.1111/ajt.15909]

73 **Liu B**, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. *Am J Transplant* 2020 [PMID: 32243673 DOI: 10.1111/ajt.15901]

74 **Qin J**, Wang H, Qin X, Zhang P, Zhu L, Cai J, Yuan Y, Li H. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology* 2020 [PMID: 32220017 DOI: 10.1002/hep.31257]

75 **Lagana SM**, De Michele S, Lee MJ, Emond JC, Griesemer AD, Tulin-Silver SA, Verna EC, Martinez M, Lefkowitch JH. COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation. *Arch Pathol Lab Med* 2020 [PMID: 32302212 DOI: 10.5858/arpa.2020-0186-SA]

76 **Karaca AS**, Ozmen MM, Ucar AD, Yastı AC, Demirer S. General Surgery Operating Room Practice in Patients with COVID-19. *Turk J Surg* 2020; **36** [DOI: 10.5578/turkjsurg.202001]

77 **Saigal S**, Gupta S, Sudhindran S, Goyal N, Rastogi A, Jacob M, Raja K, Ramamurthy A, Asthana S, Dhiman RK, Singh B, Perumalla R, Malik A, Shanmugham N, Soin AS. Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI). *Hepatol Int* 2020: 1-3 [PMID: 32270388 DOI: 10.1007/s12072-020-10041-1]

78 **BASL**. BLTG Coronavirus COVID-19 Guidance to patients with a liver transplant and chronic liver disease. Available from: <https://www.basl.org.uk>

**Footnotes**

**Conflict-of-interest statement:** The authors declare no competing interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 7, 2020

**First decision:** May 15, 2020

**Article in press:** June 9, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Soldera J, Veroux M **S-Editor:** Yan JP **L-Editor:** A **E-Editor:** Ma YJ

**Table 1 The summary of the clinical studies about acute liver injury in coronavirus infectious disease-2019**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Total patients**  | **No. of ALI, *n* (%)** | **No. of severe disease among ALI, *n* (%)**  | **Number of dismal prognosis among ALI, *n* (%)** |
| Zhou *et al*[4] | 191 | 59 (38.8) | NS | 26 (44.1) |
| Huang *et al*[24] | 41 | 15 (36.6) | 8 (53.3) | NS |
| Guan *et al*[41] | 1099 | 326 (29.7) | 94 (28.8) | 46 (14.1 |
| Hu *et al*[43] | 323 | 265 (82) | 134 (50.6) | 58 (21.9) |
| Zhang *et al*[45] | 115 | 28 (24.3) | 20 (71.4)  | NS |
| Yang *et al*[44] | 149 | 45 (30.2) | NS | NS |
| Fu *et al*[46] | 350 | 101 (28.8) | NS | 14 (13.9) |
| Cai *et al*[47] | 298 | 44 (14.7) | 21 (47.7) | NS |
| Cao *et al*[48]1 | 199 | 120 (60.3) | NS | NS |
| Shi *et al*[49] | 81 | 43 (53.1) | 26 (83.7) | NS |
| Omrani-Nava *et al*[50]  | 93 | 27 (29.2) | NS | NS |

It was considered acute liver injury if the patients had elevated alanine aminotransferase, aspartate aminotransferase, or both or if acute liver injury is reported by the authors. 1All were severe cases. ALI: Acute liver injury; No.: Number of individuals dismal prognosis: progression of the disease despite suitable therapy of occurrence of mortality in the patients; NS: Not specified.

**Table 2 The summary of the clinical studies about coronavirus infectious disease-2019 infection in patients with pre-existing liver disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Total number of Patients**  | **Number of cirrhosis, *n* (%)** | **Number severe disease among cirrhosis, *n* (%)** | **Number of dismal prognosis among cirrhosis, *n* (%)** |
| Huang *et al*[24] | 41 | 1 (2.4) | 0 | 0 |
| Guan *et al*[41]  | 1099 | 23 (2.1) | 1 (4.3) | 1 (4.3) |
| Hu *et al*[43]  | 323 | 3 (0.9) | 0 | 0 |
| Cai *et al*[47]  | 298 | 28 (9.4) | 8 (28.6) | NS |
| Shi *et al*[49]  | 81 | 7 (8.9) | 5 (71.4) | NS |
| Luo *et al*[61]  | 403 | 25 (6.2) | NS | 9 (36) |
| Luo *et al*[62]  | 298 | 16 (5.4) | NS | 5 (31.3) |

Dismal prognosis states death (*n* = 14) or progression of the disease (*n* = 1) despite suitable treatment. NS: Not specified.

**Table 3 The summary of the reported case series of coronavirus infectious disease-2019 in liver transplant recipients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Total No. of transplants** | **Age group** | **Date of LT procedure** | **No. of COVID-19 cases, *n* (%)** | **No. of deaths, *n* (%)** |
| D’Antiga[70] | 700**1** | Pediatric | NS | 3 (0.04) | 0 |
| Bhoori *et al*[71] | 151 | Adult | 111 (> 10 yr) *vs* 40 (< 2 yr) | 6 (3.9) | 3 (1.9)**2** |

1D’Antiga[70] reported the total number of pediatric patients with the liver disease treated in their institute. Seven hundred patients include 200 liver transplant recipients as well. They have not specified the 3 patients with coronavirus infectious disease-2019 (COVID-19); whether they are a transplant recipient or not is unknown; 2The three transplant recipients that died due to COVID-19 were from the long-term recipient group. The graft types were not specified in both studies. No.: The number of affected individuals; **COVID-19:** Coronavirus infectious disease-2019.

**Table 4 Summary of single case reports of coronavirus infectious disease-2019 in** **liver transplant recipients**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Sex**  | **Age**  | **LT date**  | **Type of LT** | **Etiology** | **Duration before diagnosis (d)** | **Severity of COVID-19** | **Outcome**  | **Time to outcome (d)** |
| Huang *et al*[72] | M | 59 | 2017 | NS | HBV+HCC | 3 | Severe | Died | 45 |
| Liu *et al*[73] | M | 50 | 2017 | DDLT | HBV | 6 | Severe | Recovered | 38 |
| Qin *et al*[74] | M | 37 | 2019 | NS | HBV+HCC | 9 | Mild | Recovered | 53 |
| Lagana *et al*[75] | F | 0.5 | 2020 | LDLT | Biliary atresia  | 01 | Severe | Recovered | NS2 |

**1**Lagana and colleagues have reported a pediatric living donor-recipient who contracted the virus from the donor (mother of the patient). The donor was tested positive on post-transplant day 2 and the patient was diagnosed on postoperative day 4 due to difficulty in breathing; **2The p**atient was still hospitalized with very minor respiratory symptoms. LT: Liver transplant; DDLT: Deceased donor liver transplant; LDLT: living donor liver transplantation; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; M: Male; F: Female; NS: Not specified; **COVID-19:** Coronavirus infectious disease-2019.